AbbVie DISCO Pharmaceuticals Deal: $2.54B Bet on AND-Gated Bispecifics for Solid Tumours
AbbVie pays DISCO Pharmaceuticals $40M upfront, with up to $2.5B in milestones, for options on AND-gated bispecific cancer drugs built from surfaceome mapping.
AbbVie pays DISCO Pharmaceuticals $40M upfront, with up to $2.5B in milestones, for options on AND-gated bispecific cancer drugs built from surfaceome mapping.